Press coverage about Applied Genetic Technologies Corporation (NASDAQ:AGTC) has trended somewhat negative on Monday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Applied Genetic Technologies Corporation earned a daily sentiment score of -0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 80 out of 100, indicating that recent press coverage is likely to have an effect on the stock’s share price in the immediate future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently weighed in on AGTC. Zacks Investment Research raised Applied Genetic Technologies Corporation from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Tuesday, April 11th. Stifel Nicolaus cut their target price on Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, May 11th. Cantor Fitzgerald set a $15.00 target price on Applied Genetic Technologies Corporation and gave the company a “hold” rating in a research report on Wednesday, May 10th. HC Wainwright set a $16.00 target price on Applied Genetic Technologies Corporation and gave the company a “buy” rating in a research report on Saturday, June 10th. Finally, ValuEngine downgraded Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. Applied Genetic Technologies Corporation currently has an average rating of “Hold” and an average price target of $13.81.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) opened at 4.90 on Monday. The stock’s 50 day moving average price is $5.29 and its 200 day moving average price is $7.00. The company has a market cap of $88.57 million, a P/E ratio of 11.69 and a beta of 1.71. Applied Genetic Technologies Corporation has a 52-week low of $4.70 and a 52-week high of $17.00.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last announced its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by $0.04. Applied Genetic Technologies Corporation had a return on equity of 6.62% and a net margin of 17.61%. The company had revenue of $8.39 million for the quarter, compared to analysts’ expectations of $10.39 million. During the same quarter in the previous year, the business posted $0.11 EPS. The business’s quarterly revenue was down 30.1% compared to the same quarter last year. Analysts expect that Applied Genetic Technologies Corporation will post $0.33 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Applied Genetic Technologies Corporation (AGTC) Receives Daily News Impact Score of -0.10” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/applied-genetic-technologies-corporation-agtc-receives-daily-news-impact-score-of-0-10/1444367.html.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Insider Buying and Selling by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.